Berenberg Bank reissued their buy rating on shares of GSK (LON:GSK – Free Report) in a research report report published on Wednesday morning, Marketbeat Ratings reports. The brokerage currently has a GBX 1,820 ($23.24) target price on the stock.
GSK has been the subject of a number of other reports. JPMorgan Chase & Co. reaffirmed an underweight rating on shares of GSK in a research report on Monday, July 29th. Deutsche Bank Aktiengesellschaft decreased their price objective on GSK from GBX 1,950 ($24.90) to GBX 1,850 ($23.62) and set a buy rating for the company in a research report on Wednesday, July 31st. Shore Capital reaffirmed a buy rating on shares of GSK in a research report on Thursday, June 27th. Citigroup decreased their price objective on GSK from GBX 2,120 ($27.07) to GBX 1,900 ($24.26) and set a buy rating for the company in a research report on Friday, July 5th. Finally, Barclays reaffirmed an equal weight rating and set a GBX 1,725 ($22.03) price objective on shares of GSK in a research report on Tuesday, May 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of Moderate Buy and an average price target of GBX 1,805.71 ($23.06).
Check Out Our Latest Analysis on GSK
GSK Stock Down 0.1 %
GSK Announces Dividend
The company also recently disclosed a dividend, which will be paid on Thursday, October 10th. Investors of record on Thursday, August 15th will be paid a GBX 15 ($0.19) dividend. This represents a yield of 0.97%. The ex-dividend date of this dividend is Thursday, August 15th. GSK’s payout ratio is currently 5,309.73%.
Insider Activity at GSK
In other news, insider Wendy Becker acquired 446 shares of the company’s stock in a transaction that occurred on Thursday, June 20th. The stock was purchased at an average cost of GBX 1,614 ($20.61) per share, with a total value of £7,198.44 ($9,191.06). Insiders bought 462 shares of company stock valued at $744,868 in the last ninety days. Corporate insiders own 1.61% of the company’s stock.
GSK Company Profile
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Articles
- Five stocks we like better than GSK
- Technology Stocks Explained: Here’s What to Know About Tech
- Conservative Portfolio: Strategies for Stability
- What is a Secondary Public Offering? What Investors Need to Know
- Unlocking Growth: Why Arcos Dorados Belongs in Your Portfolio
- The Risks of Owning Bonds
- Forget Robotaxis: Electric Air Taxis are the Next Big Investment
Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.